IQ-AI’s Imaging Biometrics at the forefront of brain tumour analysis

0
10
  • IQ-AI says Los Angeles County Hospital has bought subsidiary’s brain tumour imaging platform
  • IQ-AI trebles in value after impressive run of updates
  • IQ-AI present their plans to finance brain tumour trial to evaluate efficacy of Gallium Maltolate
medical imaging graphic

Quick facts: IQ-AI Ltd

Follow

View company profile

IQAI was created to accelerate the translation and commercialisation of proven imaging technologies, from the laboratory to routine clinical use, that have potential to dramatically impact the quality of life for patients facing brain tumours and other chronic diseases.

Brain tumour patients and especially those diagnosed with glioblastoma multiforme (GBM) for example face a dismal prognosis. Despite tremendous global efforts that span decades, only incremental improvements have been made in survivability and progression free survival.

The unmet clinical need of GBM and other diseases motivates IQAI to continuously innovate and deliver validated products that benefit patients. Since its inception, the company has aggressively proliferated its product portfolio, accelerated product and technology development, and obtained market clearance for new global territories.

04 Jun 2021

IQ-AI Limited () subsidiary Imaging Biometrics said its brain tumour imaging platform has been purchased by the Los Angeles County Hospital.

The deal follows the recent installation of the IB Clinic technology at the Keck Medical Center of USC, also in LA. The two run a healthcare network serving around 10mln patients.

“The automated generation of IB’s quantitative parameter maps are ideal for high-volume brain tumour centres such as USC/LAC,” IQ-AI said in a release.

“Within seconds after acquiring the MR data from the scanner, IB’s quantitative output is available for diagnostic review.”

Read more

20 Apr 2021

() the brain tumour imaging specialist, said sales momentum had started to pick up again after coronavirus disruption during the second half of 2020.

In a statement alongside results for the year to end-December, IQ-AI said that while the direct impact to operating subsidiaries, Imaging Biometrics (IB) and Stone Checker Software (SC), was negligible, hospitals and healthcare providers focused their efforts on dealing with the pandemic.

Read more

13 Apr 2021

() is to finance a phase 1 study to evaluate the safety and efficacy of Gallium Maltolate in the treatment of brain tumours.

If the trial is successful IQAI intends to apply to the US Food and Drug Administration (FDA) for orphan drug status under the FDA’s orphan drug designation programme, which grants market exclusivity in the US for seven years following approval of the drug.

Read more

09 Nov 2020

() is firing on all cylinders after a few busy weeks that saw its share price rocket three-fold.

The AIM-listed investor, which focuses on the tech sector, touched a five-year high last week after a triple dose of good news.

Read more

15 Apr 2021

Michael Schmainda, co-founder and CEO of ‘s () subsidiary Imaging Biometrics presents their plans to finance brain tumour trial to evaluate the safety and efficacy of Gallium Maltolate in the treatment of this disease.

This type of cancer, Glioblastoma is the most common and aggressive primary brain cancer and has limited treatment options and a dismal prognosis.

If the trial is successful IQAI intends to apply to the US Food and Drug Administration (FDA) for orphan drug status under the FDA’s orphan drug designation programme, which grants market exclusivity in the US for seven years following approval of the drug.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

IQ-AI present their plans to finance brain tumour trial to evaluate efficacy…

Michael Schmainda, co-founder and CEO of IQ-AI Limited’s (LON:IQAI) subsidiary Imaging Biometrics presents their plans to finance brain tumour trial to evaluate the safety and efficacy of Gallium Maltolate in the treatment of this disease.

This type of cancer, Glioblastoma is the most common…

on 15/4/21

4 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here